Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer
US-9593129-B2 · Mar 14, 2017 · US
Processes of making and crystalline forms of a MDM2 inhibitor
US9855259B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9855259-B2 |
| Application number | US-201615163186-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 24, 2016 |
| Priority date | Jun 10, 2013 |
| Publication date | Jan 2, 2018 |
| Grant date | Jan 2, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound, wherein the compound is crystalline anhydrous characterized by a powder X-ray diffraction pattern comprising at least three peaks at a diffraction angle 2 theta degrees selected from a group consisting of peaks at approximately 8.4, 11.6, 12.4, 18.6, 19.0, 23.6, and 30.4. 2. The compound of claim 1 , wherein the compound is characterized by a powder X-ray diffraction pattern comprising at least five peaks at diffraction angle 2 theta degrees selected from a group consisting of peaks at approximately 8.4, 11.6, 12.4, 18.6, 19.0, 23.6, and 30.4. 3. The compound of claim 1 , wherein the compound is characterized by a powder X-ray diffraction pattern comprising peaks at diffraction angle 2 theta degrees at approximately 8.4, 11.6, 12.4, 18.6, 19.0, 23.6, and 30.4. 4. The compound of claim 1 , wherein the X-ray diffraction pattern is obtained using CuKα radiation. 5. The compound of claim 4 , wherein the X-ray diffraction pattern is obtained at room temperature. 6. The compound of claim 2 , wherein the X-ray diffraction pattern is obtained using CuKα radiation. 7. The compound of claim 6 , wherein the X-ray diffraction pattern is obtained at room temperature. 8. The compound of claim 3 , wherein the X-ray diffraction pattern is obtained using CuKα radiation. 9. The compound of claim 8 , wherein the X-ray diffraction pattern is obtained at room temperature. 10. A pharmaceutical composition comprising the compound of claim 5 and a pharmaceutically acceptable excipient. 11. The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition is a solid dosage form. 12. The pharmaceutical composition of claim 11 , wherein the solid dosage form is a capsule, tablet, powder, or granule. 13. The pharmaceutical composition of claim 12 , wherein the solid dosage form is a tablet. 14. The pharmaceutical composition of claim 13 , wherein the solid dosage form is for oral administration.
Assignees
Inventors
Classifications
the oxygen-containing ring being five-membered · CPC title
containing only one sulfo group · CPC title
Crystalline forms, e.g. polymorphs · CPC title
- C07D211/94Primary
Oxygen atom, e.g. piperidine N-oxide · CPC title
Ortho-condensed systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9855259B2 cover?
- The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
- Who is the assignee on this patent?
- Amgen Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D211/94. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).